Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | VDR | P11473 | 1/20 | 0.51 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26426121 | 0.96 | CA1 (0.53) | CA1CA2USP2VDRST6GAL1 | |
| SCHEMBL23704719 | 0.92 | CA1 (0.56) | CA1CA2USP2 | |
| SCHEMBL23704694 | 0.89 | CA1 (0.62) | CA1CA2USP2VDREPHA2 | |
| SCHEMBL23704693 | 0.89 | CA1 (0.62) | CA1CA2USP2VDREPHA2 | |
| SCHEMBL23710501 | 0.88 | CA1 (0.56) | CA1CA2USP2 | |
| SCHEMBL23710522 | 0.87 | CA1 (0.54) | CA1CA2 | |
| SCHEMBL26425714 | 0.86 | CA1 (0.63) | CA1CA2USP2VDREPHA2 | |
| SCHEMBL30103320 | 0.86 | CA1 (0.63) | CA1CA2USP2VDREPHA2 | |
| SCHEMBL23710526 | 0.85 | CA1 (0.60) | CA1CA2USP2VDRST6GAL1 | |
| SCHEMBL23710378 | 0.85 | CA1 (0.60) | CA1CA2USP2VDRST6GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | CA1 3966/4885CA2 2810/4885USP2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.